450 related articles for article (PubMed ID: 29162334)
1. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
3. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
[TBL] [Abstract][Full Text] [Related]
4. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
7. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
Transpl Int; 2024; 37():11571. PubMed ID: 38694490
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.
Satoh S; Niioka T; Kagaya H; Numakura K; Inoue T; Saito M; Komine N; Narita S; Tsuchiya N; Habuchi T; Miura M
Pharmacogenomics; 2014 Aug; 15(11):1495-506. PubMed ID: 25303300
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
[TBL] [Abstract][Full Text] [Related]
10. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
[TBL] [Abstract][Full Text] [Related]
11. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
14. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
[No Abstract] [Full Text] [Related]
17. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
18. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
Transpl Int; 2022; 35():10225. PubMed ID: 36017158
[No Abstract] [Full Text] [Related]
19. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
